Thomas Rollins

Chief Development Officer & Head of Microbiome Program

Mr. Rollins joined Assembly from anti-infective drug developer Cubist Pharmaceuticals., where he served in various capacities, most recently overseeing global product developmentas Senior Vice President and Global Head, Program and Portfolio Management. During his tenure, Mr. Rollins contributed to the global development and commercialization of the anti-bacterial drugs Sivestro® and Zerbaxa®, which helped transform Cubist into a multi-program, multi-product company. Previously, Mr. Rollins was Senior Vice President, Program Management at Sunovion Pharmaceuticals where he led theR&D harmonization and portfolio prioritization process. Prior to Sunovion, Mr. Rollins was Senior Vice President of Development at Sepracor, where he established an efficient and productive semi-virtual drug development organization that advanced Lunesta® from IND through NDA submission in just 42 months. Earlier in his career, Mr. Rollins served as a researcher before moving to Project Management at Merck Research Laboratories, where he was co-team leader for a number of major global products, including Crixivan®, the first HIV protease inhibitor, and the pioneering osteoporosis drug Fosamax®. Mr. Rollins received BS and MS degrees from Michigan State University and an MBA from Rutgers University.